Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer.

Cancers (Basel) · 2024 · PMC10854608 · PMID 38339278

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

marginally significantp = 0.09so close (0.05 < p ≤ 0.1)

Patients with brain metastasis ( n = 13) showed a marginally significant difference in the median PFS1 compared to patients without brain metastasis ( n = 27) (13.1 months vs. 35.8 months, p = 0.09) ( Figure S1 ). 3.3.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.